Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Analyzing genes that are present in cancer cells may be useful in developing better methods to detect, predict, and treat cutaneous T-cell lymphoma. PURPOSE: Clinical trial to study genes that are present in cutaneous T-cell lymphoma cells.

Detailed Description
-----------------
OBJECTIVES: Identify gene expression patterns in malignant T cells that can be used to diagnose cutaneous T-cell lymphoma. Determine the patterns of gene expression that distinguish normal skin-homing T cells from malignant T cells. OUTLINE: Patients are stratified by disease (Sezary syndrome vs mycosis fungoides) and prior treatment (yes vs no). All patients receive a physical examination, and a medical history is taken. Patients with Sezary syndrome undergo leukapheresis. Patients with plaque/tumor stage mycosis fungoides undergo skin biopsy of involved skin. Malignant T cells from blood or skin are then isolated and patterns of gene expression in the malignant T cells are compared to those in normal skin-homing T cells from healthy donors using a gene chip (Lymphochip). Patients are followed annually for 5 years. PROJECTED ACCRUAL: A total of 40 patients (20 per disease stratum) will be accrued for this study within 2 years.

Official Title
-----------------
Gene Expression Analysis in Cutaneous T-Cell Lymphoma

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically proven mycosis fungoides with 2 or more plaques or tumors greater than 1 cm in size OR Immunologically proven Sezary syndrome with all of the following: Erythroderma Lymphadenopathy T-cell receptor variable beta chain clonality greater than 10% of total lymphocytes by flow cytometry OR CD4+CD7- T-cell fraction that represents greater than 10% of CD4+ T cells PATIENT CHARACTERISTICS: Age: 18 to 85 Performance status: Not specified Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing HIV-1 and HTLV-1 negative No prior intravenous drug use PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 2 months since prior systemic chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 2 months since prior electron beam radiotherapy Surgery: Not specified Other: At least 2 weeks since prior topical therapy At least 2 months since prior photopheresis At least 2 months since prior psoralen ultraviolet light (PUVA) or ultraviolet B (UVB) therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: laboratory biomarker analysis|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cutaneous T-cell non-Hodgkin lymphoma, mycosis fungoides/Sezary syndrome